|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Douillard JY, Cunningham D, Roth AD, et
al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: a multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar
|
|
3
|
Ikeguchi M, Arai Y, Maeta Y, Ashida K,
Katano K and Wakatsuki T: Topoisomerase I expression in tumors as a
biological marker for CPT-11 chemosensitivity in patients with
colorectal cancer. Surg Today. 41:1196–1199. 2011. View Article : Google Scholar
|
|
4
|
Calvo E, Cortes J, Rodriguez J, et al:
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination
chemotherapy in advanced colorectal carcinoma: a phase II study.
Clin Colorectal Cancer. 2:104–110. 2002. View Article : Google Scholar
|
|
5
|
Tamatani T, Azuma M, Aota K, Yamashita T,
Bando T and Sato M: Enhanced IkappaB kinase activity is responsible
for the augmented activity of NF-kappaB in human head and neck
carcinoma cells. Cancer Lett. 171:165–172. 2001. View Article : Google Scholar
|
|
6
|
Tamatani T, Azuma M, Ashida Y, et al:
Enhanced radiosensitization and chemosensitization in
NF-kappaB-suppressed human oral cancer cells via the inhibition of
gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8.
Int J Cancer. 108:912–921. 2004. View Article : Google Scholar
|
|
7
|
Lind DS, Hochwald SN, Malaty J, et al:
Nuclear factor-kappaB is upregulated in colorectal cancer. Surgery.
130:363–369. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu Y and Villalona-Calero MA: Irinotecan:
mechanisms of tumor resistance and novel strategies for modulating
its activity. Ann Oncol. 13:1841–1851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Janssens S and Tschopp J: Signals from
within: the DNA-damage-induced NF-kappaB response. Cell Death
Differ. 13:773–784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adams J: The proteasome: a suitable
antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar
|
|
11
|
Adams J: Preclinical and clinical
evaluation of proteasome inhibitor PS-341 for the treatment of
cancer. Curr Opin Chem Biol. 6:493–500. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pevzner Y, Metcalf R, Kantor M, Sagaro D
and Daniel K: Recent advances in proteasome inhibitor discovery.
Expert Opin Drug Discov. 8:537–568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Holkova B and Grant S: Proteasome
inhibitors in mantle cell lymphoma. Best Pract Res Clin Haematol.
25:133–141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tamatani T, Takamaru N, Hara K, et al:
Bortezomib-enhanced radiosensitization through the suppression of
radiation-induced nuclear factor-κB activity in human oral cancer
cells. Int J Oncol. 42:935–944. 2013.PubMed/NCBI
|
|
15
|
Cusack JC, Liu R and Baldwin AS: NF-kappa
B and chemoresistance: potentiation of cancer drugs via inhibition
of NF-kappa B. Drug Resist Updat. 2:271–273. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cusack JC Jr, Liu R, Houston M, et al:
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor
PS-341: implications for systemic nuclear factor-kappaB inhibition.
Cancer Res. 61:3535–3540. 2001.PubMed/NCBI
|
|
17
|
Cusack JC Jr, Liu R and Baldwin AS Jr:
Inducible chemoresistance to
7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin
(CPT-11) in colorectal cancer cells and a xenograft model is
overcome by inhibition of nuclear factor-kappaB activation. Cancer
Res. 60:2323–2330. 2000.PubMed/NCBI
|
|
18
|
Cusack JC Jr, Liu R, Xia L, et al:
NPI-0052 enhances tumoricidal response to conventional cancer
therapy in a colon cancer model. Clin Cancer Res. 12:6758–6764.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Demo SD, Kirk CJ, Aujay MA, et al:
Antitumor activity of PR-171, a novel irreversible inhibitor of the
proteasome. Cancer Res. 67:6383–6391. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuhn DJ, Chen Q, Voorhees PM, et al:
Potent activity of carfilzomib, a novel, irreversible inhibitor of
the ubiquitin-proteasome pathway, against preclinical models of
multiple myeloma. Blood. 110:3281–3290. 2007. View Article : Google Scholar
|
|
21
|
Adams J: Proteasome inhibition in cancer:
development of PS-341. Semin Oncol. 28:613–619. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuhn DJ, Orlowski RZ and Bjorklund CC:
Second generation proteasome inhibitors: carfilzomib and
immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug
Targets. 11:285–295. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dasmahapatra G, Lembersky D, Son MP, et
al: Carfilzomib interacts synergistically with histone deacetylase
inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol
Cancer Ther. 10:1686–1697. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zang Y, Thomas SM, Chan ET, et al:
Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of
head and neck cancer and their activities are enhanced by
suppression of Mcl-1 or autophagy. Clin Cancer Res. 18:5639–5649.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang L, Pham LV, Newberry KJ, et al: In
vitro and in vivo therapeutic efficacy of carfilzomib in mantle
cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther.
29:292013.PubMed/NCBI
|
|
26
|
Berenson JR, Hilger JD, Yellin O, et al:
Replacement of bortezomib with carfilzomib for multiple myeloma
patients progressing from bortezomib combination therapy. Leukemia.
16:272014.
|
|
27
|
Ishiyama M, Tominaga H, Shiga M, Sasamoto
K, Ohkura Y and Ueno K: A combined assay of cell viability and in
vitro cytotoxicity with a highly water-soluble tetrazolium salt,
neutral red and crystal violet. Biol Pharm Bull. 19:1518–1520.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ye YB, Lin JY, Chen Q, et al: The
cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562
cells. Biochem Pharmacol. 75:2080–2091. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar
|
|
30
|
Richardson P: Clinical update: proteasome
inhibitors in hematologic malignancies. Cancer Treat Rev. 1:33–39.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
O’Connor OA, Stewart AK, Vallone M, et al:
A phase 1 dose escalation study of the safety and pharmacokinetics
of the novel proteasome inhibitor carfilzomib (PR-171) in patients
with hematologic malignancies. Clin Cancer Res. 15:7085–7091.
2009.
|
|
32
|
Frankel A, Man S, Elliott P, Adams J and
Kerbel RS: Lack of multicellular drug resistance observed in human
ovarian and prostate carcinoma treated with the proteasome
inhibitor PS-341. Clin Cancer Res. 6:3719–3728. 2000.PubMed/NCBI
|
|
33
|
Qiao D, Gaitonde SV, Qi W and Martinez JD:
Deoxycholic acid suppresses p53 by stimulating proteasome-mediated
p53 protein degradation. Carcinogenesis. 22:957–964. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pasquini L, Petronelli A, Petrucci E, et
al: Primary ovarian cancer cells are sensitive to the proaptotic
effects of proteasome inhibitors. Int J Oncol. 36:707–713.
2010.
|
|
35
|
Yang H, Zonder JA and Dou QP: Clinical
development of novel proteasome inhibitors for cancer treatment.
Expert Opin Investig Drugs. 18:957–971. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abaza MS, Bahman AM and Al-Attiyah R:
Superior antimitogenic and chemosensitization activities of the
combination treatment of the histone deacetylase inhibitor apicidin
and proteasome inhibitors on human colorectal cancer cells. Int J
Oncol. 44:105–128. 2014.
|
|
37
|
Rosato RR, Almenara JA, Maggio SC, et al:
Role of histone deacetylase inhibitor-induced reactive oxygen
species and DNA damage in LAQ-824/fludarabine antileukemic
interactions. Mol Cancer Ther. 7:3285–3297. 2008. View Article : Google Scholar
|
|
38
|
Jares P, Colomer D and Campo E: Genetic
and molecular pathogenesis of mantle cell lymphoma: perspectives
for new targeted therapeutics. Nat Rev Cancer. 7:750–762. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Perdiguero E and Nebreda AR: Regulation of
Cdc25C activity during the meiotic G2/M transition. Cell Cycle.
3:733–737. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McConkey DJ and Zhu K: Mechanisms of
proteasome inhibitor action and resistance in cancer. Drug Resist
Updat. 11:164–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Heerdt BG, Houston MA, Mariadason JM and
Augenlicht LH: Dissociation of staurosporine-induced apoptosis from
G2-M arrest in SW620 human colonic carcinoma cells: initiation of
the apoptotic cascade is associated with elevation of the
mitochondrial membrane potential (deltapsim). Cancer Res.
60:6704–6713. 2000.
|
|
42
|
Lu D, Chen J and Hai T: The regulation of
ATF3 gene expression by mitogen-activated protein kinases. Biochem
J. 401:559–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Blonska M and Lin X: NF-kappaB signaling
pathways regulated by CARMA family of scaffold proteins. Cell Res.
21:55–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Belardo G, Piva R and Santoro MG: Heat
stress triggers apoptosis by impairing NF-kappaB survival signaling
in malignant B cells. Leukemia. 24:187–196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Milhollen MA, Traore T, Adams-Duffy J, et
al: MLN4924, a NEDD8-activating enzyme inhibitor, is active in
diffuse large B-cell lymphoma models: rationale for treatment of
NF-{kappa}B-dependent lymphoma. Blood. 116:1515–1523. 2010.
View Article : Google Scholar
|
|
46
|
Ben-Neriah Y and Karin M: Inflammation
meets cancer, with NF-kappaB as the matchmaker. Nat Immunol.
12:715–723. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ling YH, Liebes L, Zou Y and Perez-Soler
R: Reactive oxygen species generation and mitochondrial dysfunction
in the apoptotic response to Bortezomib, a novel proteasome
inhibitor, in human H460 non-small cell lung cancer cells. J Biol
Chem. 278:33714–33723. 2003. View Article : Google Scholar
|
|
48
|
Fribley A, Zeng Q and Wang CY: Proteasome
inhibitor PS-341 induces apoptosis through induction of endoplasmic
reticulum stress-reactive oxygen species in head and neck squamous
cell carcinoma cells. Mol Cell Biol. 24:9695–9704. 2004. View Article : Google Scholar
|
|
49
|
Hideshima T, Chauhan D, Richardson P, et
al: NF-kappa B as a therapeutic target in multiple myeloma. J Biol
Chem. 277:16639–16647. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zanotto-Filho A, Braganhol E, Battastini
AM and Moreira JC: Proteasome inhibitor MG132 induces selective
apoptosis in glioblastoma cells through inhibition of PI3K/Akt and
NFkappaB pathways, mitochondrial dysfunction, and activation of
p38-JNK1/2 signaling. Invest New Drugs. 30:2252–2262. 2012.
View Article : Google Scholar
|
|
51
|
Jani TS, DeVecchio J, Mazumdar T, Agyeman
A and Houghton JA: Inhibition of NF-kappaB signaling by quinacrine
is cytotoxic to human colon carcinoma cell lines and is synergistic
in combination with tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem.
285:19162–19172. 2010. View Article : Google Scholar
|
|
52
|
Weaver KD, Yeyeodu S, Cusack JC Jr,
Baldwin AS Jr and Ewend MG: Potentiation of chemotherapeutic agents
following antagonism of nuclear factor kappa B in human gliomas. J
Neurooncol. 61:187–196. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Park IH, Kim JY, Choi JY and Han JY:
Simvastatin enhances irinotecan-induced apoptosis in human
non-small cell lung cancer cells by inhibition of proteasome
activity. Invest New Drugs. 29:883–890. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Adams J: The development of proteasome
inhibitors as anticancer drugs. Cancer Cell. 5:417–421. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li X and Stark GR: NFkappaB-dependent
signaling pathways. Exp Hematol. 30:285–296. 2002. View Article : Google Scholar
|
|
56
|
Sakamoto K, Maeda S, Hikiba Y, et al:
Constitutive NF-kappaB activation in colorectal carcinoma plays a
key role in angiogenesis, promoting tumor growth. Clin Cancer Res.
15:2248–2258. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Huang S, DeGuzman A, Bucana CD and Fidler
IJ: Nuclear factor-kappaB activity correlates with growth,
angiogenesis, and metastasis of human melanoma cells in nude mice.
Clin Cancer Res. 6:2573–2581. 2000.
|
|
58
|
Garg A and Aggarwal BB: Nuclear
transcription factor-kappaB as a target for cancer drug
development. Leukemia. 16:1053–1068. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wu JT and Kral JG: The NF-kappaB/IkappaB
signaling system: a molecular target in breast cancer therapy. J
Surg Res. 123:158–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ye Q, Cai W, Zheng Y, Evers BM and She QB:
ERK and AKT signaling cooperate to translationally regulate
survivin expression for metastatic progression of colorectal
cancer. Oncogene. 29:1222013.PubMed/NCBI
|
|
61
|
Yip D, Ahmad A, Karapetis CS, Hawkins CA
and Harper PG: Matrix metalloproteinase inhibitors: applications in
oncology. Invest New Drugs. 17:387–399. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kolli-Bouhafs K, Boukhari A, Abusnina A,
et al: Thymoquinone reduces migration and invasion of human
glioblastoma cells associated with FAK, MMP-2 and MMP-9
down-regulation. Invest New Drugs. 30:2121–2131. 2012. View Article : Google Scholar : PubMed/NCBI
|
